Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 7/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.74 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.74 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.74 |
| ▸ | RARB | P10826 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | MTOR | P42345 | 7/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL6745653 | 1.00 | ADORA2B (0.74) | ADORA2BADORA3ADORA1ADORA2ARARB | |
| Ethylene SCHEMBL7664290 | 1.00 | ADORA2B (0.74) | ADORA2BADORA3ADORA1ADORA2ARARB | |
| Ethylene SCHEMBL7664296 | 1.00 | ADORA2B (0.74) | ADORA2BADORA3ADORA1ADORA2ARARB | |
| SCHEMBL5616732 | 0.98 | ADORA2B (0.74) | ADORA2BADORA3ADORA1ADORA2ARARB | |
| SCHEMBL5616731 | 0.98 | ADORA2B (0.74) | ADORA2BADORA3ADORA1ADORA2ARARB | |
| SCHEMBL6555076 | 0.98 | ADORA2B (0.74) | ADORA2BADORA3ADORA1ADORA2ARARB | |
| SCHEMBL6555070 | 0.98 | ADORA2B (0.74) | ADORA2BADORA3ADORA1ADORA2ARARB | |
| Ethylene Glycol SCHEMBL6742126 | 0.97 | ADORA2B (0.71) | ADORA2BADORA3ADORA1ADORA2ARARB | |
| Hydrochloric Acid SCHEMBL6554025 | 0.97 | ADORA2B (0.73) | ADORA2BADORA3ADORA1ADORA2ARARB | |
| SCHEMBL6554054 | 0.97 | ADORA2B (0.72) | ADORA2BADORA3ADORA1ADORA2ARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040034020-A1 | Methods of treating periodontal disease | DALUGE SUSAN MARY (US) | 2004-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040034020-A1 | Methods of treating periodontal disease | MMP8, LPO, PTGES3 | ADORA2B 680/4885ADORA3 730/4885ADORA1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.